510(K) CLEARANCES 84 ▲14RECALLS POSTED 39 ▲27CLASS I 6 ▲2PMA DECISIONS 47 ▲11WEEK ENDING / FDA DATA AS OF
Medical Device
ManufacturingTHE TRADE PAPER OF THE FACTORY FLOOR
SUBSCRIBE / SIGN IN
K141771Substantially Equivalent

Prosigna Breast Cancer Prognostic Gene Signature Assay

Nanostring Technologies, Seattle WA / Traditional, Substantially Equivalent
FDA source (opens on fda.gov)510(k) summary (opens on fda.gov)

K141771 is the FDA 510(k) clearance record for PROSIGNA BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY, a class II device, cleared for Nanostring Technologies, Inc. on under FDA product code NYI (Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer). FDA's definition for product code NYI reads: "A device which uses a gene expression profile of a breast cancer tumor, from patients stage i or stage ii lymph node negative, with a tumor size of <5.0 cm, to provide a risk assessment for distant recurrence of breast cancer. The result...". FDA records list 2 510(k) clearances for Nanostring Technologies, Inc., from to . As of , FDA records show no recalls naming K141771.

Clearance record

Decision date
Received
(129 days to decision)
Product code
NYI Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer
Regulation
21 CFR 866.6040
Device class
Class II
Review panel
Immunology
Applicant
Nanostring Technologies, Inc. 530 Fairview Ave. N, Seattle WA
510(k) summary
Summary PDF
Third party review
No

Clearances, product code NYI

Trailing 12 months

FDA records hold no clearances under product code NYI in the trailing twelve months.

FDA records show no clearances under product code NYI in the twelve months to October 2026.
Show the numbers
Monthly 510(k) clearances under FDA product code NYI, trailing twelve months
MonthClearances
November 20250
December 20250
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260
August 20260
September 20260
October 20260